Header Logo

Connection

HELEN HESLOP to Lymphoproliferative Disorders

Back to Details
This is a "connection" page, showing publications HELEN HESLOP has written about Lymphoproliferative Disorders.
HELEN HESLOP
Connection Strength
5.077
Lymphoproliferative Disorders
  1. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014 Nov; 21(6):476-81.
    View in: PubMed
    Score: 0.391
  2. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012 Sep; 9(9):510-9.
    View in: PubMed
    Score: 0.333
  3. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011 Jun; 16(3):274-80.
    View in: PubMed
    Score: 0.308
  4. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
    View in: PubMed
    Score: 0.276
  5. How I treat EBV lymphoproliferation. Blood. 2009 Nov 05; 114(19):4002-8.
    View in: PubMed
    Score: 0.273
  6. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008 Sep; 21(3):405-20.
    View in: PubMed
    Score: 0.255
  7. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005; 56:29-44.
    View in: PubMed
    Score: 0.198
  8. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol. 2004 Sep; 17(3):401-13.
    View in: PubMed
    Score: 0.193
  9. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
    View in: PubMed
    Score: 0.185
  10. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003; 110(2-3):139-48.
    View in: PubMed
    Score: 0.172
  11. High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2022 01 25; 6(2):452-459.
    View in: PubMed
    Score: 0.161
  12. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(1):1-8.
    View in: PubMed
    Score: 0.160
  13. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.156
  14. Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation. J Immunother. 2001 Jul-Aug; 24(4):283-4.
    View in: PubMed
    Score: 0.155
  15. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9.
    View in: PubMed
    Score: 0.150
  16. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145.
    View in: PubMed
    Score: 0.136
  17. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999 Mar; 11(2):96-101.
    View in: PubMed
    Score: 0.132
  18. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997 Jun; 157:217-22.
    View in: PubMed
    Score: 0.117
  19. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today. 1997 Jan; 3(1):24-30.
    View in: PubMed
    Score: 0.113
  20. Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
    View in: PubMed
    Score: 0.105
  21. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
    View in: PubMed
    Score: 0.099
  22. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
    View in: PubMed
    Score: 0.099
  23. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
    View in: PubMed
    Score: 0.093
  24. T lymphocytes targeting native receptors. Immunol Rev. 2014 Jan; 257(1):39-55.
    View in: PubMed
    Score: 0.092
  25. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8.
    View in: PubMed
    Score: 0.090
  26. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
    View in: PubMed
    Score: 0.076
  27. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93.
    View in: PubMed
    Score: 0.054
  28. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8.
    View in: PubMed
    Score: 0.052
  29. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005 Mar; 5(3):566-72.
    View in: PubMed
    Score: 0.050
  30. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005; 260-6.
    View in: PubMed
    Score: 0.049
  31. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7.
    View in: PubMed
    Score: 0.048
  32. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist. 2003; 8(1):83-98.
    View in: PubMed
    Score: 0.043
  33. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002 Sep; 118(3):728-40.
    View in: PubMed
    Score: 0.042
  34. Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children. Pediatr Radiol. 1998 Jul; 28(7):492-6.
    View in: PubMed
    Score: 0.031
  35. EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
    View in: PubMed
    Score: 0.030
  36. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998; (23):89-93.
    View in: PubMed
    Score: 0.030
  37. A yeast artificial chromosome (YAC) contig encompassing the critical region of the X-linked lymphoproliferative disease (XLP) locus. Genomics. 1997 Jan 01; 39(1):55-65.
    View in: PubMed
    Score: 0.028
  38. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.025
  39. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
    View in: PubMed
    Score: 0.025
  40. Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation. 2013 Feb 15; 95(3):519-26.
    View in: PubMed
    Score: 0.022
  41. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant. 2006 Nov-Dec; 20(6):689-94.
    View in: PubMed
    Score: 0.014
  42. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.